Clinical Trials Logo

Clinical Trial Summary

The investigators' purpose was to assess the feasibility of dosage individualization of the commonly used antineoplastic drugs and anti-infective drugs in children with hematoplastic disease.


Clinical Trial Description

The investigators' purpose was to assess the feasibility of dosage individualization of the commonly used antineoplastic drugs and anti-infective drugs based on the opportunistic sampling strategy in children with confirmed or suspected hematological neoplasms. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03844360
Study type Interventional
Source Shandong University
Contact Wei Zhao, Ph.D
Phone 86053188383308
Email zhao4wei2@hotmail.com
Status Recruiting
Phase Phase 4
Start date January 31, 2016
Completion date December 31, 2021

See also
  Status Clinical Trial Phase
Completed NCT00440479 - ADVANCE: An Observational Study To Determine Bortezomib Safety and Effectiveness at First Relapse After Participation In First Line HOVON-49/50 Clinical Studies. Phase 4
Completed NCT00410696 - Pegfilgrastim Versus Filgrastim After High-dose Chemotherapy Phase 2
Completed NCT02223052 - Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies Phase 1
Completed NCT00440765 - VALEO: A Post Authorization Study, Designed to Learn More About the Safety and Effectiveness of the Use of Bortezomib in the Netherlands Phase 4
Completed NCT02544230 - Granulocyte Transfusions in Hematological Patients With Febrile Neutropenia N/A
Completed NCT00582894 - Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Malignant Hematological Diseases N/A
Completed NCT02634294 - Peg Interferon α-2b for Relapsed Hematological Malignancies After Allo-HSCT Phase 2/Phase 3